Pharmacogenetics and coumarin dosing--recalibrating expectations.
about
Revitalizing personalized medicine: respecting biomolecular complexities beyond gene expression.Learning from biomedical linked data to suggest valid pharmacogenes.Implementation and utilization of genetic testing in personalized medicine.Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.Pharmacogenetics in Jewish populations.Pragmatic and Ethical Challenges of Incorporating the Genome into the Electronic Medical Record.A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics.Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial.Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencingGenotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials.Genotype-guided coumarin dosing: where are we now and where do we need to go next?Personalized medicine: Genetic risk prediction of drug response.The genetics of drug efficacy: opportunities and challenges.Functional Study of the Vitamin K Cycle Enzymes in Live Cells.Evidence and resources to implement pharmacogenetic knowledge for precision medicine.Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1.A systematic analysis and comparison of warfarin initiation strategies.Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration.Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.Genetics in the 21st Century: Implications for patients, consumers and citizens.Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort.Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin.Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition.
P2860
Q33570878-DB1F5145-4B54-48BC-A771-9C8851236007Q33587530-829064A7-1E16-4BBB-A35E-B26AEFD2B33AQ34147916-B101F7DB-976A-4C1B-9324-E6E23656CAEBQ34284362-70AACFAC-2B66-4804-B396-B94459E83D4BQ34458720-4220AAB6-F8A9-44DD-85D4-F367809F67A5Q35809920-2D3ED3D4-64A6-474B-A092-8517C64982C9Q35888757-2C50C4D3-B74C-4792-A8E8-881E06AEB7ACQ36195396-40179EC5-03B8-4447-866C-5C71FFDA0751Q37156736-3C91FDD7-9F7E-42E3-A068-846A82E92335Q38233757-A8690722-AB2C-4B15-B882-4819B9170BE1Q38321269-7E665839-0129-4993-90C9-32469A02AC45Q38756015-7835D00A-9B11-4A40-96A7-381D07EB5F4FQ38773033-396FBBD9-A649-48CC-A326-471EF0D2C405Q39074534-636AD85A-98D4-4FFA-891B-28B1A7D3F605Q39173298-53881D9E-B386-40C1-99E5-306E72E36311Q40367486-B87F48AD-0EBE-4748-97AB-8B61C77FC505Q40665013-8A276221-FE64-4624-BE2D-F1244542169BQ40862073-7336DCB3-B8A9-4B07-B1F4-D1A532B02401Q41014816-048FF95B-FA9D-4C40-9F88-55440A3F350CQ47149360-6C361955-F024-40E9-A1D8-2444B509F38FQ47212625-4C43C522-1F68-417E-A58F-88932FF6E684Q47728750-101CDFE8-217E-47E5-8099-3B9C70DF76F8Q47837577-6A5B17E4-482F-4939-A2E0-EC97023D5E76Q53823783-CCC5BD00-19CD-47C2-A4F4-4094C8352D19
P2860
Pharmacogenetics and coumarin dosing--recalibrating expectations.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Pharmacogenetics and coumarin dosing--recalibrating expectations.
@en
Pharmacogenetics and coumarin dosing--recalibrating expectations.
@nl
type
label
Pharmacogenetics and coumarin dosing--recalibrating expectations.
@en
Pharmacogenetics and coumarin dosing--recalibrating expectations.
@nl
prefLabel
Pharmacogenetics and coumarin dosing--recalibrating expectations.
@en
Pharmacogenetics and coumarin dosing--recalibrating expectations.
@nl
P2093
P356
P1476
Pharmacogenetics and coumarin dosing--recalibrating expectations.
@en
P2093
Issam Zineh
Janet Woodcock
Michael Pacanowski
P304
P356
10.1056/NEJMP1314529
P407
P577
2013-12-01T00:00:00Z